These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 34923127)
1. Re: Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study: authors' response. Shasha D; Heymann AD; Zacay G Clin Microbiol Infect; 2022 Mar; 28(3):454-455. PubMed ID: 34923127 [No Abstract] [Full Text] [Related]
2. Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study' by Shasha et al. Scorza FA; Finsterer J Clin Microbiol Infect; 2022 Mar; 28(3):452-453. PubMed ID: 34839005 [No Abstract] [Full Text] [Related]
3. Disseminated herpes zoster in an immune-competent patient after SARS-CoV-2 vaccine (BNT162b2 Comirnaty, Pfizer). Zengarini C; Misciali C; Ferrari T; Dika E; La Placa M; Piraccini BM; Baraldi C J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):e622-e623. PubMed ID: 35429051 [No Abstract] [Full Text] [Related]
4. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia. Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883 [TBL] [Abstract][Full Text] [Related]
5. Pityriasis lichenoides chronica after BNT162b2 Pfizer-BioNTech vaccine: A novel cutaneous reaction after SARS-CoV-2 vaccine. Drago F; Ciccarese G; Guadagno A; Parodi A J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):e979-e981. PubMed ID: 35841285 [No Abstract] [Full Text] [Related]
6. Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data. van den Ouweland F; Charpentier N; Türeci Ö; Rizzi R; Mensa FJ; Lindemann C; Pather S Hum Vaccin Immunother; 2024 Dec; 20(1):2315659. PubMed ID: 38407186 [TBL] [Abstract][Full Text] [Related]
7. Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases. Fornaro M; Venerito V; Iannone F; Cacciapaglia F J Rheumatol; 2022 Mar; 49(3):334-335. PubMed ID: 35033998 [No Abstract] [Full Text] [Related]
8. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis. Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256 [TBL] [Abstract][Full Text] [Related]
9. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study. Haslak F; Gunalp A; Cebi MN; Yildiz M; Adrovic A; Sahin S; Barut K; Kasapcopur O Int J Rheum Dis; 2022 Mar; 25(3):353-363. PubMed ID: 34978376 [TBL] [Abstract][Full Text] [Related]
10. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months. Ponticelli D; Antonazzo IC; Caci G; Vitale A; Della Ragione G; Romano ML; Borrelli M; Schiavone B; Polosa R; Ferrara P J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34697627 [No Abstract] [Full Text] [Related]
11. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women. Goldshtein I; Nevo D; Steinberg DM; Rotem RS; Gorfine M; Chodick G; Segal Y JAMA; 2021 Aug; 326(8):728-735. PubMed ID: 34251417 [TBL] [Abstract][Full Text] [Related]
12. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines. Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093 [TBL] [Abstract][Full Text] [Related]